Sant og greit sagt.!!
2 Likes
Det er mye på spill for Modena, prestisje og ikke minst en haug med penger, de har lovende resultater fra de første 50 behandlet med deres vaksine, men det må to injeksjoner til for å danne antikropper.
Dannes det nok anti-kropper til å stå i mot en smitte og hvor lenge varer forsvaret, forsøkspersonene i første gruppe er sannsynlig ikke den mest utsatte gruppen i befolkningen og normalt vet vi at den utsatte del av befolkningen også har et nedsatt immunforsvar.
Det er ikke rasjonelt å tro at ikke Modena har kjennskap til PCI sin teknologi, men kan de komme i mål alene ville de fleste i Modenas situasjon foretrukket det alternativet.
Det er konkurrenter der ute og riktig mange, med to injeksjoner er de allerede der hvor 2 besøk er nødvendig, kostnaden ved 2 besøk eskalerer kostnader og prisen på vaksinen, kan konkurrentene oppvise samme respons ved en behandling er de slått.
PCI sin teknologi krever også en ekstra behandling kunne denne vært forbigått med et “lys-plaster” som aktiverte automatisk etter en tid og var så billig å produsere at den kunne kastes etter belysning.Det er heller ikke praktisk eller ønskelig i en smittevernslituasjon med gjenbruk.
I det minste vet vi at Donal Trump har en stor forkjærlighet for lys, om noen gir han rett i det han har blitt sterkest kritisert for “nemlig lys og innvendig vask” ville dette vært gull i valgkampen, kanskje noen bure tipse han.
6 Likes
Glimrende 
Og som du skriver:
«PCI sin teknologi krever også en ekstra behandling kunne denne vært forbigått med et “lys-plaster” som aktiverte automatisk etter en tid og var så billig å produsere at den kunne kastes etter belysning.Det er heller ikke praktisk eller ønskelig i en smittevernslituasjon med gjenbruk.«
PCI Biotech har til overmål et patentert lysplaster! Aktiveres gjerne hjemme og rimelig og kan kastes etter bruk om det er ønskelig. Men ved bruk hjemme er gjenbruk på en og samme person god smittevern.
PW går gjennom patentet både i radforsk podcast en Q presentasjon mener jeg.
Meget interessant det du skriver 
6 Likes
Dagens virus er en ting.
Men Pcib sitter med en leveringstekologi, og tre ben, ( spesielt i forhold til kreft m. m. der det kan lyses) som nok ikke har gått opp for de fleste .
Men B.F. har nok oversikt over det som er, det bør man regne med. Dagens prisvandring er nok bare et forspill.
Mest spennende synes jeg det blir med krefthåndtering i årene framover. Betryggende.
6 Likes
Fokus på ballen, ikke spilleren!
Spydspissen er GGK og det er nok her pcib kommer til å blåse sokkene av enhver lille og store investor etterhvert…
Bare så synd at børsen sjelden gidder å vente og må hele tiden mates med nyheter for å holde på noen aksjonærer, så derfor bra med vacc og nac…
11 Likes
Blås i aksjekurs & eventuell dans.
Det er (den langsiktige) forskningen, og resultatene, som er interessant.
Og nå er flere tiårs forskning nærme målet.
I vår periode!
7 Likes
Kommer de i gang i Asia er veien kort til markedet tror jeg.Er såpass mye bedre en alt annet at det er uforsvarlig og ikke gi Chem grønt lys.Tipper om ca 1 år er vi i gang. Vi sitter på en rakettaksje børsen ikke har sett siden Opticom.Ta plass, og på med hjelm og bli sittende.
13 Likes
Bli sittende - som i eksempelet ditt 
2 Likes
Tipper vi prisen mai 2021 ? 
2 Likes
Når det gjelder GGK har Pcib blåst sokkene av de fleste allerede.
Men Pcib har tre ben. De fleste andre har ett.
Hvem står stødigst i storm/forskning og mediaoppmerksomhet og i forhold til framtidens sykdomshåndtering. ?
Det selskapet som har mer enn ett ben, - og i tillegg kan hjelpe fleste (gode) legemiddelprodusenter som har leveringsvanskeligheter.
Leveringsvansker, overmedisinering og bivirkninger.
Tre ting, - som Pcib med sine tre ben kan hjelpe til med.
7 Likes
AstraZeneca is not slowing down!
Drug delivery scientists – formulation/analytical
locations Cambridge, England, United Kingdom Gothenburg, Västra Götaland County, Sweden Job ID R-082082 Date posted 05-18-2020
Några highlights:
We are now looking for drug delivery scientistswith strong expertise in the formulation and analytical sciences to work on delivering new modalities for gene therapy.
New modalities for gene therapy; nya sätt att påverka gener, hej fimaNac
You will be involved in establishing and driving close research collaborations across academia and small biotech companies . Small Biotech companies
- Experience of formulating colloidal products such as lipid nanoparticles, polymeric delivery vehicles, other nanoparticle technologies, injectables or emulsions.
Fimaporfin is an injectable
-
Strong technical knowledge of nucleic-acid based drug delivery technologies
-
Experience working with nanomedicines and experience formulating intracellular delivery systems for nucleotides and/or proteins
Intracellular delivery systems anyone
- A working knowledge of CRISPR-related biology and a good knowledge of endosomal biology
Endosomal biology : the core of PCIB
Drug Delivery Scientists – Formulation/Analytical
Cambridge UK, Gothenburg Sweden
At AstraZeneca we turn ideas into life changing medicines and strive to continuously meet the unmet needs of patients worldwide. Working here means being entrepreneurial, thinking big, and working together to make the impossible a reality. If you are swift to action, confident to lead, willing to collaborate, and curious about what science can do, then you’re our kind of person.
Pharmaceutical Sciences at AstraZeneca deliver the therapies of the future through scientific leadership in drug delivery, design of synthetic routes, and manufacturing of Active Pharmaceutical Ingredients (API) and drug products. Our portfolio of projects spans traditional small molecules, peptides, oligonucleotides to RNA based therapeutics across AstraZeneca’s therapy areas. Advanced Drug Delivery (ADD) resides within Pharmaceutical Sciences with a mission to provide novel products to AstraZeneca’s clinical pipeline.
We are now looking for drug delivery scientistswith strong expertise in the formulation and analytical sciences to work on delivering new modalities for gene therapy.
In this role you will be responsible for design and characterisation of formulations for the delivery of nucleic acids. This will involve working with advanced drug delivery platforms such as lipid nanoparticles. Working in close collaboration with peers in the advanced drug delivery group, you will continually be improving our end to end formulation design, characterisation and testing capabilities. As part of the team you will serve on global drug project teams working with scientists across UK, US and Sweden. You will also be expected to drive science networks and provide high quality scientific input across the organisation.
You will be involved in establishing and driving close research collaborations across academia and small biotech companies . We expect you to be an active member of the external scientific community enhancing our reputation as scientific leaders in the advanced drug delivery field.
We are seeking ambitious scientists with a strong foundation in the delivery sciences and a specialisation in the formulation and analytical sciences as well as a great passion for experimental science. This is a hands-on, lab-based position where you will work with different teams, so you should like communicating and have the capacity to share your data.
If you are committed to developing your career in the pharmaceutical sciences – this might be the role for you!
The location for these positions are flexible between Cambridge, UK and Gothenburg, Sweden.
Essential Requirements
- PhD or Master’s degree in pharmaceutical sciences, biology, chemistry or a related discipline
- Experience of formulating colloidal products such as lipid nanoparticles, polymeric delivery vehicles, other nanoparticle technologies, injectables or emulsions.
- Strong technical knowledge of nucleic-acid based drug delivery technologies
- Experience in analytical instrumentations used in formulation characterization (particle size and zeta potential measurements, pKa determination etc.)
- Strong record of scientific excellence evidenced by publications, patents and presentations
- Thorough understanding of principles, applications and management of Safety Health and Environment (SHE)
Desirable Requirements
- Practical skills for the design and synthesis and purification of new materials to support nucleic acid delivery efforts
- Practical skills with cell based and in vivo assays to assess the performance of nanomedicines
- Experience working with nanomedicines and experience formulating intracellular delivery systems for nucleotides and/or proteins
- A working knowledge of CRISPR-related biology and a good knowledge of endosomal biology
Are you ready to make a difference? Send in your application, and we’ll make it happen together.
Application Open 18/05/2020
Application Close 19/06/2020
AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorisation and employment eligibility verification requirements.
61 Likes
Flere stillinger?
Edit: ser slik ut:
The location for these positions are flexible between Cambridge, UK and Gothenburg, Sweden.
5 Likes
Tolkar det som flera. Position:s and scientist:s båda i plural =)
4 Likes
Forhandlingene går med andre ord bra.
5 Likes
AZ akter tydeligvis ikke å sløse bort dyrbar tid når tilgangen er i boks.
Full gass
7 Likes
Mens vi venter på en god nyhet så kan det være forfriskende å lese bloggen til NTNU som omhandler mulighet for suksess ang
Effective induction of cytotoxic T-cells will be critical to realise the huge potential of therapeutic cancer vaccines…
2018
https://blog.medisin.ntnu.no/en/can-light-help-to-develop-effective-anti-cancer-vaccination/
We performed experiments with PCI vaccination technology both in a cell culture system as well as in a mouse model. We found that PCI-mediated vaccine delivery to immune cells made vaccines 30-100-fold more effective in activating CTL responses compared to vaccine-delivery without PCI technology. In addition, it was found that the PCI vaccination treatment in itself had an enhancing (“adjuvant”) effect by stimulating immune cells, probably due to the low-grade cell damage generated by the treatment. We could confirm these findings in mice by demonstrating that PCI vaccination was able to effectively induce specific CTL responses to two cancer antigens. We thus show new and compelling evidence that PCI technology may provide a feasible strategy to improve the outcome of vaccines that aim at inducing CTL responses that can fight cancer cells.
15 Likes
Fasit til vente-quiz for PCI Biotech-nerder som ikke har nerver til kursprat
Takk for den enorme oppslutningen… Sukk! Jeg som trodde nerdefaktoren her var høy. 
Spydkasteren heter Ásdís Hjálmsdóttir. Hun har vært mesterskapsdeltager for Island i spyd. Hennes doktorarbeid som førte til disputas i 2018, ble utført ved University of Zurich. Les oppgaven (PhD thesis) her:
https://doi.org/10.5167/uzh-152755
Hjálmsdóttir, Ásdís. The many moods of liposomes: an investigation into liposomes as mediators of difficult immune responses. 2018, University of Zurich, Faculty of Science.
ANTIGEN DELIVERY DEVICE AND METHOD
Patent number: 10166401
Abstract: A device for activating light-induced rupture of endocytic vesicles in target cells of a patient so as to effect delivery of an administered antigen to cytosol in the target cells, is described. The device is adapted to be worn by a patient over a region of skin where an antigen and a photosensitising agent are to be administered. The device comprises a rear surface that is rounded or otherwise configured to be worn against the patient’s skin. It has a retaining part for retaining the device in place over the region of the patient’s skin during an activation cycle. A light source is arranged to illuminate the patient’s skin from the rear of the device. A control system is configured to vary the output of the light source with respect to time in accordance with a pre-configured output sequence.
Type: Grant
Filed: August 28, 2014
Date of Patent: January 1, 2019
Assignee: PCI BIOTECH AS
Inventors: Anders Hogset, Per Edvard Walday, Kristin Eivindvik
fimaNAc pga Nucleic Acids
21 Likes
Ved siden av FimaChem/Vacc, så venter vi alle på AZ og FimaNac.
La oss anta at AZ signerer en eller flere avtaler med PCIB.
Pål Falck sa at AZ sannsynlighet hadde “forkjøpsrett” til å evt signere en/flere FimaNac avtaler.
Hva når de er signert, da er det store muligheter for de neste på lista til å sikre seg avtaler innen FimaNac…
Slik som Per og PCIB har presset AZ, har de antagelig flere avtaler i sikte…
Dette blir heelt råått de neste mnd/år 
12 Likes
Kikket gjennom denne artikkelen som kom i februar og her og her er det mye interessant som ikke minst er høyaktuelt nå som vi nærmer oss 30/6…
Noen utdrag:
Thus, while for mRNA it seems very important to induce endosomal release rapidly after uptake (Høgset et al., manuscript in preparation),
Thus, in on-going animal experiments very promising results have been achieved using PCI for mRNA delivery to skin and to tumours (Høgset et al., manuscript in preparation)
Spesielt det siste er svært interessant ettersom artikkelen ble levert inn 20/12/2018. Høgset jobbet da med en publikasjon på mRNA dyreforsøk. Vi vet fra før at AZ og PCIB har blitt enige om å publisere de lovende dataene. Så at det er AZ forsøkene vi snakker om her kan vi være ganske sikre på.
Very promising
Skal vi spekulere litt er “delivery to skin” de forsøkene som ikke går på kreft…
Videre, er det et avsnitt om tox som er interessant. Levering med lipider er kjent for å gi mer tox problematikk enn naken levering:
“It is therefore
very interesting that PCI is able to enhance nucleic acid delivery with such vehicles in amounts far
below what is needed for the induction of endosomal escape by the “proton sponge” effect
potentially making it possible to use the vehicles also for in vivo applications where vehicle toxicity would normally be of concern”
Tar med dette avsnittet også:
“Polycations can be used for effecting nucleic acid uptake by conferring a positive charge to the
negatively charged nucleic acids so that a polycation/nucleic acid complex can be taken up after
electrostatic interaction with the negatively charged cell surface. This is a general uptake mechanism that works very well in combination with PCI with many types of nucleic acids ranging from PNAs conjugated to positively charged amino acids [163,217] thorough poly-amino acid mediated delivery of plasmids and mRNA [159,166], to adenovirus coated with polycations [208]. To the extent that the employed polycations are not able to induce a “proton sponge” effect, such systems will often have very low gene delivery efficiency on their own, meaning that PCI can be used to literally turn delivery on, with enhancement factors up to >100 times being observed [85,190]. Thus, such systems could be
very useful in situations where a strict spatio-temporal control over the delivery is desired”
47 Likes
Det er enorme forbedringer vaar leveringseknologi kan frembringe. Kan ikke forstaa annet enn at vi gaar en fin fremtid i moete! Og at sommerens presentasjoner, og partnering strategi vil oppnaa stor suksess. Noe som starter allerede neste uke. The next generation…
10 Likes